Knight Therapeutics (GUD.TO) Stock Analysis & Winston Score

Knight Therapeutics is a Canadian pharmaceutical company that buys the rights to sell medicines in Latin America and Canada that were originally developed by other companies. It focuses on specialty drugs — treatments for cancer, rare diseases, and infections — and sells them to hospitals, clinics, and pharmacies across more than a dozen countries. Knight does not invent its own drugs; instead, it acts as a regional distributor and commercializer for medicines made elsewhere. The company makes money by purchasing or licensing drugs, then selling them to healthcare providers at a markup. It operates primarily across Latin America, with a smaller presence in Canada, and generates roughly $200–250 million in annual revenue. Its competitive edge comes from its regional regulatory expertise and established distribution networks, which are hard for outside companies to quickly replicate. The main risk is that thin operating margins — currently below 3% — leave little room for error, and the business depends heavily on successfully acquiring new drug licenses to sustain growth.